Justine Bruce
Medical Oncology · Madison, WINPI 1164518692
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,428 of the $25,434 with a category attached, or 80.3%. 7 manufacturers reported payments, led by Sanofi at 42.1% of the total. Among medical oncology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $1017.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$11K
- GSK$6K
- Eli Lilly$5K
- Merck$2K
- Pfizer$1K
- Coherus Oncology, Inc.$140
- plus $133 from 1 others
Across 414 payments — averaging $7189.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1M
- Astellas Pharma Global Development$569K
- Merck$536K
- Eli Lilly$448K
- Seagen Inc.$337K
- Pfizer$63K
What the payments were for
- Consulting fees$20,42880%
- Speaking & faculty fees$1,7257%
- Travel & lodging$2,64110%
- Food & beverage$6413%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 11 | $10,697 |
| GSK | 7 | $6,282 |
| Eli Lilly | 3 | $5,282 |
| Merck | 1 | $1,500 |
| Pfizer | 1 | $1,400 |
| Coherus Oncology, Inc. | 1 | $140 |
| Genentech USA, Inc. | 1 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,434 in reported general payments places this provider in the 90th percentile of 54 medical oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LenvimaLenvatinib Mesylate | 21 | $484,394 |
| Prochlorperazine Maleate | 44 | $527 |
| Ondansetron Hcl | 53 | $527 |
| Levothyroxine Sodium | 35 | $462 |
| Olanzapine | 25 | $268 |
| Potassium Chloride | 11 | $236 |
| Dexamethasone | 17 | $225 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Madison
- Joshua LangMadison$114K
- Dustin DemingMadison$100K
- Kari WisinskiMadison$43K
- Glenn LiuMadison$13K
- Toby CampbellMadison$12K
- Douglas McNeelMadison$7K
- Noelle LoconteMadison$4K
- Anthony SerritellaMadison$2K
- Howard BaileyMadison$553
- George WildingMadison$383
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.